Increased arterial intima-media thickness in childhood-onset growth hormone deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 5, 1997, Pages 1378-1381

  Capaldo, Brunella ^a,b   Patti, Lidia ^a   Oliviero, Ugo ^a   Longobardi, Salvatore ^a   Pardo, Francesco ^a   Vitale, Flavia ^a   Fazio, Serafino ^a   Di Rella, Francesca ^a   Biondi, Bernadette ^a   Lombardi, Gaetano ^a   Saccà, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GLUCOSE; GROWTH HORMONE; INSULIN; LIPOPROTEIN; LIPOPROTEIN A; TRIACYLGLYCEROL;

ADULT; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR;

EID: 8244225987     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.5.3951     Document Type: Article

References (31)

1. Rosen T, Bengtsson B-Å. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:283-288.
2. Markussis V, Beshyah SA, Fisher, Sharp P, Nicolaides AN, Johnston DG. 1992 Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 340:1188-1192.
3. Merimee TJ, Hollander W, Fineberg SE. 1972 Studies of hyperlipidemia in the HG-deficient state. Metabolism. 21:1053-1061.
4. Libber SM, Plotnick LP, Johanson AJ, Blizzard RM, Kwiterovitch PO, Migeon CJ. 1990 Long-term follow-up of hypopituitary patients treated with human growth hormone. Medicine. 69:46-55.
5. Rosen TE, Eden S, Larson G, Wilhelmsen L, Bengtsson B-Å. 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 129:195-200.
6. DeBoer H, Blok GJ, Voerman HJ, Philips M, Schouten JA. 1994 Serum lipid levels in growth hormone-deficient men. Metab Clin Exp. 43:199-202.
7. Cuneo FC, Salomon F, Watts GF, Hesp R, Sönksen PH. 1993 Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism. 42:1519-1523.
8. Snel Yem, Doerga ME, Brummer RM, Zelissen PMJ, Koppeschaar HPF. 1995 Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Arterioscler Thromb Vasc Biol. 15:1543-1548.
9. Alford F, Hew FL, Koschmann M, Cristopher M, Rantzau C, Ward G. 1994 Defects of glucose metabolism in growth hormone deficient (GHD) adults. Endocrinol Metab. [Suppl B]1:27.
10. O'Neal DN, Kalfas A, Dunning PL, et al. 1944 The effects of three months of recombinant human growth hormone (rhGH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults. J Clin Endocrinol Metab. 79:975-983.
11. Hew FL, Koschman M, Christopher M, et al. 1996 Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab. 81:555-564.
12. Saccà L, Cittadini A, Fazio S. 1994 Growth hormone and the heart. Endocr Rev. 15:555-573.
13. Ghigo E, Mazza E, Imperiale E, et al. 1987 The enhancement of the colinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone induced GH secretion in children of short stature. J Clin Endocrinol Metab. 65:452-456.
14. Gil-Aid I, Topper E, Laron L. 1977 Oral clonidine as a growth hormone stimulation test. Lancet. 2:278-279.
15. Cocozza M, Picano T, Oliviero U, Russo N, Coto V, Milani M. 1995 Effects of the picotamide, an antithromboxane agent, on carotid atherosclerosis evolution. A two-year double blind placebo-controlled study in diabetic patients. Stroke. 26:597-601.
16. Hatch FT, Lees RS. 1969 Practical methods for plasma lipoprotein analysis. In: Paoletti R, Kritchevsky D, eds. Advances in lipid research. London: Academic Press; 1-68.
17. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. 1977 Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem. 23:882-884.
18. Grafnetter D. 1977 World Health Organization (WHO) coordinated quality control in lipid laboratory. Giorn Arterioscl. 2:113-128.
19. Marbet GA, Duckert F. 1992 Fibrinogen. In: Jesperson J, Bertina RM, Haverkate F, eds. ECAT assay procedures. A manual of laboratory results. Dordrecht, Netherlands: Kluwer; 47-55.
20. WHO. 1980 Expert Committee on Diabetes Mellitus. 2nd Report. Technical report series no. 646. Geneva: World Health Organization.
21. Powrie J, Weissberger A, Sönksen P. 1995 Growth hormone replacement therapy for growth hormone-deficient adults. Drugs. 49:656-663.
22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. 1986 Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 74:1399-1406.
23. Bonithon-Kopp C, Touboul P-J, Berr C, et al. 1996 Relation of intima-media thickness to atherosclerotic plaques in carotid arteries. The vascular aging (EVA) study. Arterioscler Thromb Vasc Biol. 16:310-316.
24. Stewart MW, Laker MF, Dyer RG, et al. 1993 Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperinsulinemia. Arterioscler Thromb. 13:1046-1052.
25. Selby JV, Austin MA, Newman B, et al. 1993 LDL subclasses phenotypes and the insulin resistance syndrome in women. Circulation. 88:381-387.
26. Wolfsdorf JI, Sadeghi-Hejad A, Senior B. 1983 Hypoketonaemia and age-related fasting hypoglycemia in growth hormone deficiency. Metab Clin Exp. 32:457-462.
27. Scanu AM, Fless GM. 1990 Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest. 85:1709-1715.
28. Ernst E. 1991 Fibrinogen: an independent risk factor for cardiovascular disease. Br Med J. 303:596-597.
29. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. 1994 Direct demonstration of insulin-like growth factor-1-induced nitric oxide production by endothelial cells. Kidney Int. 45:598-604.
30. Boger RH, Skamira C, Bode-Boger SM, Brabant G, von zur Muhlen A, Frolich JC. 1996 Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest. 98:2706-2713.
31. Radomski MW, Salas E. 1995 Nitric oxide-biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis. 118(Suppl):S69-S80.